Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07209960 in advanced solid tumors
NCT04628780Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Dec 2020
- Primary completion
- May 2023
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of PF-07209960 in non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (HNSCC), renal cell carcinoma (RCC) and 3 more (4 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Dose Limiting Toxicities, Number of Participants With Treatment-Emergent Adverse Events up to 16.6 months and 5 more. Started Dec 2020; status: terminated.
02
Drugs
PF-07209960
03
Conditions
non-small cell lung cancer (NSCLC)squamous cell carcinoma of the head and neck (HNSCC)renal cell carcinoma (RCC)urothelial carcinoma (UC)colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT04628780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04628780.